0 citations0 references

Subtype‐specific mutation of PPP2R1A in endometrial and ovarian carcinomas

The Journal of Pathology2011Vol. 223(5), pp. 567–573

Citations Over TimeTop 10% of 2011 papers

Melissa K. McConechy, Michael S. Anglesio, Steve E. Kalloger, Winnie Yang, Janine Senz, Christine Chow, Alireza Heravi‐Moussavi, Gregg B. Morin, Anne‐Marie Mes‐Masson, Australian Ovarian Cancer Study Group, Mark Carey, Jessica N. McAlpine, Janice S. Kwon, Leah Prentice, Niki Boyd, Sohrab P. Shah, C. Blake Gilks, David G. Huntsman

Abstract

PPP2R1A mutations have recently been described in 3/42 (7%) of clear cell carcinomas of the ovary. PPP2R1A encodes the α-isoform of the scaffolding subunit of the serine/threonine protein phosphatase 2A (PP2A) holoenzyme. This putative tumour suppressor complex is involved in growth and survival pathways. Through targeted sequencing of PPP2R1A, we identified somatic missense mutations in 40.8% (20/49) of high-grade serous endometrial tumours, and 5.0% (3/60) of endometrial endometrioid carcinomas. Mutations were also identified in ovarian tumours at lower frequencies: 12.2% (5/41) of endometrioid and 4.1% (2/49) of clear cell carcinomas. No mutations were found in 50 high-grade and 12 low-grade serous carcinomas. Amino acid residues affected by these mutations are highly conserved across species and are involved in direct interactions with regulatory B-subunits of the PP2A holoenzyme. PPP2R1A mutations in endometrial high-grade serous carcinomas are a frequent and potentially targetable feature of this disease. The finding of frequent PPP2R1A mutations in high-grade serous carcinoma of the endometrium but not in high-grade serous carcinoma of the ovary provides clear genetic evidence that these are distinct diseases.

Related Papers

→ Prognostic Values of Transforming Growth Factor‐Beta Subtypes in Ovarian Cancer(2020)16 cited
→ Radioimmunoscintigraphy of Ovarian Tumours with Tc-99m Labelled Monoclonal Antibody-170(1995)1 cited
[Betaglucuronidase activity in ovarian carcinoma (author's transl)].(1979)
[Expression of EVEC in ovarian carcinoma and its biological significance].(2010)
→ On the Validity of Simultaneous Determinations of CA 125, SRA, and CA 72-4 in Patients Suffering from Ovarian Tumors(1993)1 cited